Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
2(50.0%)
4Total
N/A(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05518500Phase 4Active Not Recruiting

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Role: lead

NCT05528796Not ApplicableEnrolling By Invitation

Uncovering the Etiologies of Non-immune Hydrops Fetalis

Role: collaborator

NCT03936101Completed

Prenatal Genetic Diagnosis by Genomic Sequencing

Role: collaborator

NCT03104075Phase 4Completed

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

Role: lead

NCT04838834Completed

Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children

Role: collaborator

NCT04066816Not ApplicableCompleted

Ellagic Acid, Urolithin and Colonic Microbial Communities Affected by Walnut Consumption

Role: collaborator

All 6 trials loaded